Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer.

IF 0.7 Q4 SURGERY

Journal of radiosurgery and SBRT Pub Date : 2022-01-01

Rashad Rzazade, Ngoc T Pham, Menekse Turna, Mehmet Dogu Canoglu, Esra Kucukmorkoc, Kezban Berberoglu, Hale Basak Caglar

{"title":"Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer.","authors":"Rashad Rzazade, Ngoc T Pham, Menekse Turna, Mehmet Dogu Canoglu, Esra Kucukmorkoc, Kezban Berberoglu, Hale Basak Caglar","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with adrenal gland metastasis (AGM) of oligometastatic lung cancer.Methods: Between June 2013 and May 2021, 44 patients with oligometastatic lung cancer (51 AGMs) were treated with SBRT. Forty-six (90%) lesions received a biological effective dose (BED10, α/β = 10) of 100 Gy. The primary endpoint was local control (LC). Local control (LC), overall survival (OS), and progression-free survival (PFS) curves were calculated by the Kaplan-Meier method.Results: The median follow-up was 23 months. The most common histology was non-small cell lung cancer (88.6%). The 1- and 2-year LC rates were both 95% and 91%, respectively. Overall survival was better in patients with solitary AGMs in univariate analysis.Conclusion: This study demonstrated that SBRT with higher BED is associated with satisfactory LC and low toxicity rates in patients with AGM of oligometastatic lung cancer.","PeriodicalId":16917,"journal":{"name":"Journal of radiosurgery and SBRT","volume":"8 4","pages":"275-282"},"PeriodicalIF":0.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322168/pdf/rsbrt-8-275.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of radiosurgery and SBRT","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with adrenal gland metastasis (AGM) of oligometastatic lung cancer.

Methods: Between June 2013 and May 2021, 44 patients with oligometastatic lung cancer (51 AGMs) were treated with SBRT. Forty-six (90%) lesions received a biological effective dose (BED₁₀, α/β = 10) of 100 Gy. The primary endpoint was local control (LC). Local control (LC), overall survival (OS), and progression-free survival (PFS) curves were calculated by the Kaplan-Meier method.

Results: The median follow-up was 23 months. The most common histology was non-small cell lung cancer (88.6%). The 1- and 2-year LC rates were both 95% and 91%, respectively. Overall survival was better in patients with solitary AGMs in univariate analysis.

Conclusion: This study demonstrated that SBRT with higher BED is associated with satisfactory LC and low toxicity rates in patients with AGM of oligometastatic lung cancer.

Abstract Image

本刊更多论文

立体定向放射治疗肾上腺转移性少转移性及少进展性肺癌。

目的:评价立体定向放射治疗(SBRT)治疗少转移肺癌肾上腺转移(AGM)的疗效和安全性。方法:2013年6月至2021年5月，44例低转移性肺癌患者(51例AGMs)接受SBRT治疗。46例(90%)病变接受100 Gy的生物有效剂量(BED10， α/β = 10)。主要终点为局部控制(LC)。采用Kaplan-Meier法计算局部控制(LC)、总生存(OS)和无进展生存(PFS)曲线。结果:中位随访时间为23个月。最常见的组织学为非小细胞肺癌(88.6%)。1年和2年的贷款利率分别为95%和91%。单因素分析显示，孤立性AGMs患者的总生存率更高。结论:本研究表明，在低转移性肺癌AGM患者中，高BED的SBRT与令人满意的LC和低毒性率相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of radiosurgery and SBRT SURGERY-

CiteScore

1.40

自引率

8.30%

发文量